Equity Profile

INSM

Insmed Incorporated

Health CareBiotechnology$27.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insmed Incorporated is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Insmed's work is crucial as it addresses unmet medical needs, particularly in rare diseases.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue Growth

Revenue growth is essential to gauge the company's market traction and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

In Q1 2026, Insmed reported an EPS of -$0.76, which was better than the expected -$0.90, resulting in a positive surprise. However, the stock fell 23.41% the following day, indicating market disappointment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Insmed's upcoming earnings are mixed, with uncertainty surrounding revenue growth and profitability. Investors are keen to see if the company can maintain its momentum or if challenges persist.

Bull Case

The optimistic view hinges on Insmed demonstrating strong revenue growth and improving its EPS, which could signal successful product uptake and operational efficiency.

Bear Case

Conversely, if Insmed fails to show meaningful revenue growth or reports a larger-than-expected loss, it could lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for the quarter?

Revenue growth is critical for assessing the company's market performance and future potential, especially given recent volatility.

How does management plan to address the ongoing losses?

Understanding management's strategy for improving profitability will be key for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insmed's potential for revenue growth due to its innovative pipeline, which could lead to stronger-than-expected demand.

Supporting Evidence

The options market is pricing a 21.56% move, suggesting significant uncertainty that may not align with the company's growth trajectory.

Insmed's recent EPS surprise indicates that the company has the potential to outperform expectations despite recent losses.

Key Risk

If revenue growth exceeds 15%, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will provide insights into Insmed's ability to navigate market challenges and capitalize on growth opportunities.

Bull Confirmed If

Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

Reporting a loss greater than -$0.90 EPS would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations and raises guidance, history suggests the stock could see an average 16.33% increase on the first day.

In-Line / Cautious

An in-line report with cautious commentary may lead to a muted response, reflecting the market's uncertainty.

Miss

If the company misses expectations, the average reaction has been a decline of around 1.98%, indicating potential further downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth and product uptake in key markets.
2Management's strategy for addressing ongoing losses and improving profitability.
3Updates on any new product developments or regulatory approvals.
4Insights into market conditions and competitive landscape.
5Any changes in guidance for future quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue Growth

Revenue growth is essential to gauge the company's market traction and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on Insmed demonstrating strong revenue growth and improving its EPS, which could signal successful product uptake and operational efficiency.

Bear Case

Conversely, if Insmed fails to show meaningful revenue growth or reports a larger-than-expected loss, it could lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate for the quarter?

Revenue growth is critical for assessing the company's market performance and future potential, especially given recent volatility.

How does management plan to address the ongoing losses?

Understanding management's strategy for improving profitability will be key for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insmed's potential for revenue growth due to its innovative pipeline, which could lead to stronger-than-expected demand.

Supporting Evidence

The options market is pricing a 21.56% move, suggesting significant uncertainty that may not align with the company's growth trajectory.

Insmed's recent EPS surprise indicates that the company has the potential to outperform expectations despite recent losses.

Key Risk

If revenue growth exceeds 15%, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will provide insights into Insmed's ability to navigate market challenges and capitalize on growth opportunities.

Bull Confirmed If

Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

Reporting a loss greater than -$0.90 EPS would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations and raises guidance, history suggests the stock could see an average 16.33% increase on the first day.

In-Line / Cautious

An in-line report with cautious commentary may lead to a muted response, reflecting the market's uncertainty.

Miss

If the company misses expectations, the average reaction has been a decline of around 1.98%, indicating potential further downside.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth and product uptake in key markets.
2Management's strategy for addressing ongoing losses and improving profitability.
3Updates on any new product developments or regulatory approvals.
4Insights into market conditions and competitive landscape.
5Any changes in guidance for future quarters.